Doripenem

CHEMBL491571 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
420.5 g/mol
LogP
-3.4
Phase
4

A broad-spectrum carbapenem antibiotic used to treat serious bacterial infections, particularly those caused by resistant gram-negative bacteria. It works by disrupting bacterial cell wall synthesis.

Berat Molekul

420,5000 g/mol

LogP

-3,40

TPSA

196,00 Ų

Lipinski RO5

Lulus

Mekanisme Kerja

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12

InChI

InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1

Molecular Formula

C15H24N4O6S2

HBD / HBA

5 / 10

Ikatan yang Dapat Dirotasi

7

Atom Berat

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A broad-spectrum carbapenem antibiotic used to treat serious bacterial infections, particularly those caused by resistant gram-negative bacteria. It works by disrupting bacterial cell wall synthesis.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Doripenem is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL491571. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 73303. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.